

Refine Search

Search Results -

Term	Documents
1.PGPB.	157
(L1).PGPB.	157

Database:

- US Pre-Grant Publication Full-Text Database
- US Patents Full-Text Database
- US OCR Full-Text Database
- EPO Abstracts Database
- JPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Search:

Refine Search

Recall Text
Clear
Interrupt

Search History

DATE: Wednesday, September 13, 2006 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set</u>	<u>Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side				result set
DB=PGPB; PLUR=YES; OP=ADJ	<u>L4</u>	L1	157	<u>L4</u>
DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ	<u>L3</u>	L1	3	<u>L3</u>
DB=USPT; PLUR=YES; OP=ADJ	<u>L2</u>	L1	37	<u>L2</u>
DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ	<u>L1</u>	(lfa-1 or cd11 or cd11a)same(cd40L or cd154 or gp39 or cd40 adj ligand or 5c8)same(ctla\$ or b7\$)	197	<u>L1</u>

END OF SEARCH HISTORY

e au=townsend robert ?

Ref	Items	Index-term
E1	1	AU=TOWNSEND ROB
E2	21	AU=TOWNSEND ROBERT
E3	0	*AU=TOWNSEND ROBERT ?
E4	2	AU=TOWNSEND ROBERT A
E5	3	AU=TOWNSEND ROBERT J
E6	16	AU=TOWNSEND ROBERT M
E7	1	AU=TOWNSEND ROBERT MARTIN
E8	2	AU=TOWNSEND ROBERT REID
E9	10	AU=TOWNSEND ROBERT W
E10	1	AU=TOWNSEND ROBERTA A
E11	1	AU=TOWNSEND ROD
E12	3	AU=TOWNSEND RONALD R

Enter P or PAGE for more

? s e6-e7

16	AU=TOWNSEND ROBERT M
1	AU=TOWNSEND ROBERT MARTIN
S1	17 E6-E7

? e au=peach robert ?

Ref	Items	Index-term
E1	6	AU=PEACH RICHARD K
E2	28	AU=PEACH -ROBERT
E3	0	*AU=PEACH ROBERT ?
E4	15	AU=PEACH ROBERT J
E5	26	AU=PEACH S
E6	1	AU=PEACH S C
E7	5	AU=PEACH S E
E8	2	AU=PEACH S F
E9	1	AU=PEACH S G
E10	1	AU=PEACH S J
E11	12	AU=PEACH S L
E12	10	AU=PEACH S.

Enter P or PAGE for more

? s e2-e4

28	AU=PEACH ROBERT
0	AU=PEACH ROBERT ?
15	AU=PEACH ROBERT J
S2	43 E2-E4

? s (s1 or s2) and cta4?

17	S1
43	S2
4839	CTLA4?
S3	23 (S1 OR S2) AND CTLA4?

? rd s3

S4	20 RD S3 (unique items)
----	-------------------------

? s s4 and (lfa? or cd11a or cd11?) and (cd154 or cd40L or cd40(w)ligand or gp39)

20	S4
----	----

18887	LFA?
-------	------

7402	CD11A
------	-------

34995	CD11?
-------	-------

3221	CD154
------	-------

7032	CD40L
------	-------

28506	CD40
-------	------

469767	LIGAND
--------	--------

13455	CD40(W)LIGAND
-------	---------------

718	GP39
-----	------

S5	0 S4 AND (LFA? OR CD11A OR CD11?) AND (CD154 OR CD40L OR
----	--

CD40 (W) LIGAND OR GP39)

? t s4/3/all

4/3/1 (Item 1 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014441795 BIOSIS NO.: 200300400514
The effects of B7-dependent costimulation on T cell division and survival
in vivo and in vitro are dependent on antigen concentration.
AUTHOR: Lumsden Joanne M; Prasad Simon J; Peach Robert J; Ronchese
Franca (Reprint)
AUTHOR ADDRESS: Malaghan Institute of Medical Research, P.O. Box 7060,
Wellington South, New Zealand**New Zealand
AUTHOR E-MAIL ADDRESS: fronchese@malaghan.org.nz
JOURNAL: European Journal of Immunology 33 (8): p2074-2082 August 2003
2003
MEDIUM: print
ISSN: 0014-2980 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/2 (Item 2 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014135090 BIOSIS NO.: 200300093809
Co-stimulatory molecules in islet xenotransplantation: CTLA4Ig
treatment in CD40 ligand-deficient mice.
AUTHOR: Benda Birgitta; Ljunggren Hans-Gustaf; Peach Robert; Sandberg
Jan-Olov; Korsgren Olle (Reprint)
AUTHOR ADDRESS: Section of Clinical Immunology, Department of Oncology,
Radiology and Clinical Immunology, The Rudbeck Laboratory, Uppsala
University, SE-751 85, Uppsala, Sweden**Sweden
AUTHOR E-MAIL ADDRESS: Olle.Korsgren@klinimm.uu.se
JOURNAL: Cell Transplantation 11 (7): p715-720 2002 2002
MEDIUM: print
ISSN: 0963-6897
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/3 (Item 3 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013996307 BIOSIS NO.: 200200589818
In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80
blockade potentiates CD8+ T cell activation and CTL effector function
AUTHOR: Lang Thomas J (Reprint); Nguyen Phuong; Peach Robert; Gause
William C; Via Charles S
AUTHOR ADDRESS: Division of Rheumatology and Clinical Immunology,
University of Maryland School of Medicine, 10 South Pine Street, MSTF
8-34, Baltimore, MD, 21201, USA**USA
JOURNAL: Journal of Immunology 168 (8): p3786-3792 April 15, 2002 2002
MEDIUM: print
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract

LANGUAGE: English

4/3/4 (Item 4 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013846502 BIOSIS NO.: 200200440013
Bacterial pathogens induce abscess formation by CD4+ T-cell activation via
the CD28-B7-2 costimulatory pathway
AUTHOR: Tzianabos Arthur O (Reprint); Chandraker Anil; Kalka-Moll Wiltrud;
Stingele Francesca; Dong Victor M; Finberg Robert W; Peach Robert;
Sayegh Mohamed H
AUTHOR ADDRESS: Channing Laboratory, 181 Longwood Ave., Boston, MA, 02115,
USA**USA
JOURNAL: Infection and Immunity 68 (12): p6650-6655 December, 2000 2000
MEDIUM: print
ISSN: 0019-9567
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/5 (Item 5 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013106725 BIOSIS NO.: 200100278564
B7 requirements for primary and secondary protein- and
polysaccharide-specific Ig isotype responses to streptococcus pneumoniae
AUTHOR: Wu Zhengqi (Reprint); Khan Abdul (Reprint); Shen Yi (Reprint);
Schartman Jerome (Reprint); Peach Robert (Reprint); Lees Andrew
(Reprint); Mond James J (Reprint); Gause William C (Reprint); Snapper
Clifford M (Reprint)
AUTHOR ADDRESS: UHUHS, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA**
USA
JOURNAL: FASEB Journal 15 (4): pA310 March 7, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: Annual Meeting of the Federation of American Societies
for Experimental Biology on Experimental Biology 2001 Orlando, Florida,
USA March 31-April 04, 2001; 20010331
ISSN: 0892-6638
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

4/3/6 (Item 6 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013000759 BIOSIS NO.: 200100172598
CD28-B7-mediated T cell costimulation in chronic cardiac allograft
rejection: Differential role of B7-1 in initiation versus progression of
graft arteriosclerosis.
AUTHOR: Kim Kyung Soo; Denton Mark D; Chandraker Anil; Knoflach Andreas;
Milord Rolando; Waaga Anna Maria; Turka Laurence A; Russell Mary E;
Peach Robert; Sayegh Mohamed H (Reprint)
AUTHOR ADDRESS: Laboratory of Immunogenetics and Transplantation, Brigham
and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA,
02115, USA**USA
JOURNAL: American Journal of Pathology 158 (3): p977-986 March, 2001 2001

MEDIUM: print
ISSN: 0002-9440
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/7 (Item 7 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0012998298 BIOSIS NO.: 200100170137
CTLA4/CD28Ig hybrid fusion proteins and uses thereof
AUTHOR: Linsley Peter S; Ledbetter Jeffrey A; Bajorath Jurgen; Peach
Robert (Reprint); Brady William
AUTHOR ADDRESS: Edmonds, WA, USA**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents 1236 (3): July 18, 2000 2000
MEDIUM: e-file
PATENT NUMBER: US 6090914 PATENT DATE GRANTED: July 18, 2000 20000718
PATENT CLASSIFICATION: 530-350 PATENT ASSIGNEE: Bristol-Myers Squibb
Company PATENT COUNTRY: USA
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

4/3/8 (Item 8 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0012873179 BIOSIS NO.: 200100045018
Blockade of costimulation and IL-12 prevents immunopathology in IL-10 KO
mice after infection with T. gondii
AUTHOR: Wille Ulrike (Reprint); Villegas Eric N (Reprint); Craig Linden
(Reprint); Peach Robert; Hunter Christopher A (Reprint)
AUTHOR ADDRESS: School of Veterinary Medicine, University of Pennsylvania,
Philadelphia, PA, USA**USA
JOURNAL: FASEB Journal 14 (6): pA980 April 20, 2000 2000
MEDIUM: print
CONFERENCE/MEETING: Joint Annual Meeting of the American Association of
Immunologists and the Clinical Immunology Society Seattle, Washington, USA
May 12-16, 2000; 20000512
ISSN: 0892-6638
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

4/3/9 (Item 9 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0012658916 BIOSIS NO.: 200000377229
CD28-B7 blockade prevents the development of experimental autoimmune
glomerulonephritis
AUTHOR: Reynolds John (Reprint); Tam Frederick W K; Chandraker Anil; Smith
Jennifer; Karkar Ayman M; Cross Jane; Peach Robert; Sayegh Mohamed
H; Pusey Charles D
AUTHOR ADDRESS: Renal Section, Division of Medicine, Imperial College
School of Medicine, Hammersmith Hospital, Du Cane Road, London, W12 0NN,

UK**UK
JOURNAL: Journal of Clinical Investigation 105 (5): p643-651 March, 2000
2000
MEDIUM: print
ISSN: 0021-9738
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/10 (Item 10 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0012029870 BIOSIS NO.: 199900289530
Costimulatory signal blockade in murine relapsing experimental autoimmune
encephalomyelitis
AUTHOR: Schaub Meike; Issazadeh Shohreh; Stadlbauer Thomas H W; Peach
Robert; Sayegh Mohamed H; Khouri Samia J (Reprint)
AUTHOR ADDRESS: Harvard Medical School, Brigham and Women's Hospital, 77
Louis Pasteur Avenue, Boston, MA, 02115, USA**USA
JOURNAL: Journal of Neuroimmunology 96 (2): p158-166 May 3, 1999 1999
MEDIUM: print
ISSN: 0165-5728
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/11 (Item 11 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0011853147 BIOSIS NO.: 199900112807
CTLA4-Ig inhibits optimal T helper 2 cell development but not
protective immunity or memory response to *Nippostrongylus brasiliensis*
AUTHOR: Harris Nicola L; Peach Robert J; Ronchese Franca (Reprint)
AUTHOR ADDRESS: Malaghan Inst. Med. Res., P.O. Box 7060, Wellington South,
New Zealand**New Zealand
JOURNAL: European Journal of Immunology 29 (1): p311-316 Jan., 1999 1999
MEDIUM: print
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/12 (Item 12 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0011278142 BIOSIS NO.: 199800072389
CD28-B7 blockade in organ dysfunction secondary to cold
ischemia/reperfusion injury: Rapid, communication
AUTHOR: Chandraker Anil; Takada Moriatsu; Nadeau Kari C; Peach Robert
; Tilney Nicholas L; Sayegh Mohamed H (Reprint)
AUTHOR ADDRESS: Brigham and Women's Hosp., 75 Francis St., Boston, MA
02115, USA**USA
JOURNAL: Kidney International 52 (6): p1678-1684 Dec., 1997 1997
MEDIUM: print
ISSN: 0085-2538
DOCUMENT TYPE: Article

RECORD TYPE: Abstract
LANGUAGE: English

4/3/13 (Item 13 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0010745741 BIOSIS NO.: 199799379801
CD80 costimulation is essential for the induction of airway eosinophilia
AUTHOR: Harris Nicola; Peach Robert; Naemura Joe; Linsley Peter S; Le
Gros Graham; Ronchese Franca (Reprint)
AUTHOR ADDRESS: Malaghan Inst. Med. Res., P.O. Box 7060, Wellington South,
New Zealand**New Zealand
JOURNAL: Journal of Experimental Medicine 185 (1): p177-182 1997 1997
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/14 (Item 14 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0010685297 BIOSIS NO.: 199799319357
Costimulatory function and expression of CD40 ligand, CD80, and CD86 in
vascularized murine cardiac allograft rejection
AUTHOR: Hancock Wayne W; Sayegh Mohamed H; Zheng Xiang-Guang; Peach
Robert; Linsley Peter S; Turka Laurence A (Reprint)
AUTHOR ADDRESS: Univ. Pennsylvania, 409 BRB-I, 422 Curie Boulevard,
Philadelphia, PA 19104-6069, USA**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United
States of America 93 (24): p13967-13972 1996 1996
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/15 (Item 15 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0010626956 BIOSIS NO.: 199699261016
Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86
regulate T cell costimulatory interactions
AUTHOR: Greene Joanne L; Leytze Gina M; Emswiler John; Peach Robert;
Bajorath Jurgen; Cosand Wesley; Linsley Peter S (Reprint)
AUTHOR ADDRESS: Bristol-Myers Squibb Pharm. Res. Inst., 3005 First Ave.,
Seattle, WA 98121, USA**USA
JOURNAL: Journal of Biological Chemistry 271 (43): p26762-26771 1996 1996
ISSN: 0021-9258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/16 (Item 16 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0010080495 BIOSIS NO.: 199598548328
CTLA4Ig: A novel immunoglobulin chimera with immunosuppressive properties
AUTHOR: Peach Robert J; Linsley Peter S
AUTHOR ADDRESS: Bristol-Myers Squibb Pharmaceutical Res. Inst., 3005 First Ave., Seattle, WA 98121, USA**USA
JOURNAL: Methods (Orlando) 8 (2): p116-123 1995 1995
ISSN: 1046-2023
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

4/3/17 (Item 17 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0010031859 BIOSIS NO.: 199598499692
Both extracellular immunoglobulin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28
AUTHOR: Peach Robert J (Reprint); Bajorath Jürgen; Naemura Joseph; Leytze Gina; Greene Joanne; Aruffo Alejandro; Linsley Peter S
AUTHOR ADDRESS: Bristol-Myers Squibb Pharmaceutical Res. Inst., 3005 First Ave., Seattle, WA 98121, USA**USA
JOURNAL: Journal of Biological Chemistry 270 (36): p21181-21187 1995 1995
ISSN: 0021-9258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/18 (Item 18 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0009581933 BIOSIS NO.: 199598049766
Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1
AUTHOR: Peach Robert J (Reprint); Bajorath Jürgen; Brady William; Leytze Gina; Greene Joanne; Naemura Joseph; Linsley Peter S
AUTHOR ADDRESS: Bristol-Myers Squibb Pharm. Res. Inst., 3005 First Ave., Seattle, WA 98121, USA**USA
JOURNAL: Journal of Experimental Medicine 180 (6): p2049-2058 1994 1994
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/19 (Item 1 from file: 155)
DIALOG(R) File 155: MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

15328933 PMID: 15707398
Rational development of LEA29Y (belatacept), a high-affinity variant of ***CTLA4*** -Ig with potent immunosuppressive properties.
Larsen Christian P; Pearson Thomas C; Adams Andrew B; Tso Paul; Shirasugi Nozomu; Stroberm Elizabeth; Anderson Dan; Cowan Shannon; Price Karen; Naemura Joseph; Emswiler John; Greene JoAnne; Turk Lori Ann; Bajorath Jürgen; Townsend Robert; Hagerty David; Linsley Peter S; Peach Robert J
Emory Transplant Center, Department of Surgery, School of Medicine, Emory

University Atlanta, Georgia, USA. clarsen@emoryhealthcare.org
American journal of transplantation - official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (Denmark) Mar 2005, 5 (3) p443-53, ISSN 1600-6135--Print
Journal Code: 100968638

Contract/Grant No.: P51-RR00165; RR; NCRR; R01-AI40519; AI; NIAID; U19-AI44644; AI; NIAID; U19-AI51731; AI; NIAID

Publishing Model Print; Comment in Am J Transplant. 2005 Mar;5(3) 423-4; Comment in PMID 15707394

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

4/3/20 (Item 2 from file: 155)
DIALOG(R) File 155: MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

13740046 PMID: 12004346

Costimulatory blockade prevents early rejection, promotes lymphocyte apoptosis, and inhibits the upregulation of intragraft interleukin-6 in an orthotopic liver transplant model in the rat.

Bartlett Adam S; McCall John L; Ameratunga Rohan; Howden Brian; Yeong Mee-Ling; Benjamin Christopher D; Hess Donna; Peach Robert; Munn Stephen R

Division of Surgery, University of Auckland, New Zealand.

Liver transplantation - official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (United States) May 2002, 8 (5) p458-68, ISSN 1527-6465--Print Journal Code: 100909185

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

? s ctla4? and (lfa? or cd11a or cd11?) and (cd154 or cd40L or cd40(w)ligand or gp39)

4839 CTLA4?

18887 LFA?

7402 CD11A

34995 CD11?

3221 CD154

7032 CD40L

28506 CD40

469767 LIGAND

13455 CD40(W)LIGAND

718 GP39

S6 31 CTLA4? AND (LFA? OR CD11A OR CD11?) AND (CD154 OR CD40L OR CD40(W)LIGAND OR GP39)

? s s6 and mofetil

31 S6

13179 MOFETIL

S7 0 S6 AND MOFETIL

? s (ctla4? or (lfa? or cd11a or cd11?) or (cd154 or cd40L or cd40(w)ligand or gp39)) and mofetil

4839 CTLA4?

18887 LFA?

7402 CD11A

34995 CD11?

3221 CD154

7032 CD40L

28506 CD40
469767 LIGAND
13455 CD40(W)LIGAND
718 GP39
13179 MOFETIL
S8 189 (CTLA4? OR (LFA? OR CD11A OR CD11?) OR (CD154 OR CD40L OR CD40(W)LIGAND OR GP39)) AND MOFETIL
? s s8 and (toleran? or graft? or transplant?)
189 S8
467303 TOLERAN?
643312 GRAFT?
1710754 TRANSPLANT?
S9 160 S8 AND (TOLERAN? OR GRAFT? OR TRANSPLANT?)
? rd s9
S10 89 RD S9 (unique items)
? s s10 and py<2000
Processing
89 S10
48433545 PY<2000
S11 10 S10 AND PY<2000
? t s11/3/all

11/3/1 (Item 1 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0012263560 BIOSIS NO.: 199900523220
Stable mixed hematopoietic chimerism in dogs given donor antigen,
CTLA4Ig, and 100 cGy total body irradiation before and
pharmacologic immunosuppression after marrow transplant
AUTHOR: Storb Rainer (Reprint); Yu Cong; Zaucha J Maciej; Deeg H Joachim;
Georges George; Kiem Hans-Peter; Nash Richard A; McSweeney Peter A;
Wagner John L
AUTHOR ADDRESS: Fred Hutchinson Cancer Research Center, 1100 Fairview Ave
N, D1-100, Seattle, WA, 98109-1024, USA**USA
JOURNAL: Blood 94 (7): p2523-2529 Oct. 1, 1999 ***1999***
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/2 (Item 2 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0011848539 BIOSIS NO.: 199900108199
Stable mixed hematopoietic chimerism in dogs given CTLA4Ig and 100
cGy total body irradiation before and pharmacological immunosuppression
after marrow transplant
AUTHOR: Yu C; Zaucha J; Nash R; Deeg H J; Storb R
AUTHOR ADDRESS: Fred Hutchinson Cancer Res. Cent., Seattle, WA, USA**USA
JOURNAL: Blood 92 (10 SUPPL. 1 PART 1-2): p262A Nov. 15, 1998 ***1998***
MEDIUM: print
CONFERENCE/MEETING: 40th Annual Meeting of the American Society of
Hematology Miami Beach, Florida, USA December 4-8, 1998; 19981204
SPONSOR: The American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Citation
LANGUAGE: English

11/3/3 (Item 3 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0010410722 BIOSIS NO.: 199699044782
Effects of mycophenolic acid mofetil on acute rejection of kidney
allografts in rats
AUTHOR: Heemann U (Reprint); Azuma H; Schmid C; Philipp T; Tilney N
AUTHOR ADDRESS: NTP-Ambulanz, Abt. Nephrol., Univ. Essen, Hufelandstr. 55,
D-45122 Essen, Germany**Germany
JOURNAL: Clinical Nephrology 45 (5): p355-357 1996 1996
ISSN: 0301-0430
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/4 (Item 4 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0009724651 BIOSIS NO.: 199598192484
Effects of RS61443 on functional and morphological changes in chronically
rejecting rat kidney allografts
AUTHOR: Azuma Haruhito; Binder Jochen; Heemann Uwe; Schmid Christof;
Tullius Stefan G; Tilney Nicholas L (Reprint)
AUTHOR ADDRESS: Dep. Surgery, Brigham and Women's Hosp., 75 Francis St.,
Boston, MA 02115, USA**USA
JOURNAL: Transplantation (Baltimore) 59 (4): p460-466 1995 1995
ISSN: 0041-1337
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/5 (Item 1 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

07585450 EMBASE No: 1999080750
Inhibition of endothelial receptor expression and of T-cell ligand
activity by mycophenolate mofetil
Blaheta R.A.; Leckel K.; Wittig B.; Zenker D.; Oppermann E.; Harder S.;
Scholz M.; Weber S.; Schuldes H.; Encke A.; Markus B.H.
R.A. Blaheta, JW Goethe-University-Hospital, Department of General
Surgery, Transplant-Immunology Laboratory, Theodor-Stern-Kai 7, D-60590
Frankfurt am Main Germany
AUTHOR EMAIL: Blaheta@em.uni-frankfurt.de
Transplant Immunology (TRANSPLANT IMMUNOL.) (United Kingdom) 1998, 6/4
(251-259)
CODEN: TRIME ISSN: 0966-3274
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 22

11/3/6 (Item 2 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

07511124 EMBASE No: 1998411784
New immunosuppressive strategies
Keown P.A.
P.A. Keown, Immunology Laboratory, Vancouver General Hospital, 855 West
12th Avenue, Vancouver, BC V5Z 1M9 Canada
AUTHOR EMAIL: keown@unixg.ubc.ca
Current Opinion in Nephrology and Hypertension (CURR. OPIN. NEPHROL.
HYPERTENS.) (United Kingdom) 1998, 7/6 (659-663)
CODEN: CNHYE ISSN: 1062-4821
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 45

11/3/7 (Item 3 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

07020660 EMBASE No: 1997310412
Investigation of infiltration blocking properties of myophenolate
mofetil (cellcept(R))
UNTERSUCHUNGEN ZUR INFILTRATIONSHEMMENDEN EIGENSCHAFT VON MYCOPHENOLAT
MOFETIL (CELLCEPT(R))
Blaheta R.A.; Wittig B.; Leckel K.; Scholz M.; Weber S.; Kronenberger B.;
Auth M.; Encke A.; Markus B.H.
Dr. R.A. Blaheta, Klin. der J. W. Goethe-Universitat, Klinik fur
Allgemeinchirurgie, TIL, Theodor Stern Kai 7, D-60590 Frankfurt am Main
Germany
Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft
(TRANSPLANTATIONSMED. ORGAN DTSCH. TRANSPLANTATIONSGES.) (Germany)
1997, 9/3 (128-131)
CODEN: ZETRE ISSN: 0946-9648
DOCUMENT TYPE: Journal; Article
LANGUAGE: GERMAN SUMMARY LANGUAGE: ENGLISH; GERMAN
NUMBER OF REFERENCES: 11

11/3/8 (Item 4 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

06535742 EMBASE No: 1996193382
Synergistic effects of mycophenolate mofetil (MMF, RS-61443) and
anti- LFA-1/ICAM-1 monoclonal antibodies on the prolongation of heart
allograft survival in rats
Takazawa K.; Hosoda Y.; Bashuda H.; Seino K.; Yagita H.; Tamatani T.;
Miyasaka M.; Okumura K.
Department of Cardiothoracic Surgery, Juntendo Univ. School of Medicine,
2-1-1 Hongo, Bunkyo-Ku, Tokyo 113 Japan
Transplantation Proceedings (TRANSPLANT. PROC.) (United States) 1996,
28/3 (1980-1981)
CODEN: TRPPA ISSN: 0041-1345
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH

11/3/9 (Item 5 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

06507432 EMBASE No: 1996174181
Mycophenolate mofetil inhibits lymphocyte binding and the

upregulation of adhesion molecules in acute rejection of rat kidney allografts

Heemann U.; Azuma H.; Hamar P.; Schmid C.; Tilney N.; Philipp T.
NTP-Ambulanz, Department of Nephrology, University Hospital Essen,
Hufelandstrasse 55, 45122 Essen Germany

Transplant Immunology (TRANSPLANT IMMUNOL.) (United Kingdom) 1996, 4/1
(64-67)

CODEN: TRIME ISSN: 0966-3274

DOCUMENT TYPE: Journal; Conference Paper

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

11/3/10 (Item 1 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

12429801 PMID: 10371508

Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates.

Kirk A D; Burkly L C; Batty D S; Baumgartner R E; Berning J D; Buchanan K ; Fechner J H; Germond R L; Kampen R L; Patterson N B; Swanson S J; Tadaki D K; TenHoor C N; White L; Knechtle S J; Harlan D M

The Naval Medical Research Center, Immune Cell Biology Program, Bethesda, Maryland 20889, USA.

Nature medicine (UNITED STATES) Jun 1999, 5 (6) p686-93,

ISSN 1078-8956--Print Journal Code: 9502015

Publishing Model Print; Comment in Nat Med. 1999 Jun;5(6) 616-7; Comment in PMID 10371494

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

? t s11/kwic/all

>>>KWIC option is not available in file(s): 399

11/KWIC/1 (Item 1 from file: 5)

DIALOG(R) File 5:(c) 2006 The Thomson Corporation. All rts. reserv.

Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant 1999

...ABSTRACT: a sublethal dose of 200 cGy total body irradiation (TBI) before and immunosuppression with mycophenolate mofetil (MMF) and cyclosporine (CSP) for 28 and 35 days, respectively, after dog leukocyte antigen-identical marrow ***transplantation***. Most likely, the role of pretransplant TBI was to provide host immunosuppression, since stable mixed...

...nodes, was substituted for TBI. When TBI was reduced from 200 to 100 cGy, all ***grafts*** were rejected within 3 to 12 weeks. Here, we asked whether stable engraftment after 100...

...by first reducing the intensity of host immune responsiveness with help of the fusion peptide CTLA4Ig, which blocks T-cell costimulation through the B7-CD28 signal pathway. Accordingly, recipient T cells...

...per day on days -7 to -1 before 100 cGy TBI, with concurrent administration of ***CTLA4Ig*** 4 mg/kg/d IV. All 7 dogs so treated showed initial mixed chimerism. Two...

...unirradiated marrow and lymph node spaces, for now more than 46 to 70 weeks after ***transplant*** . Data support the hypothesis that stable marrow allografts can be established by combining nonmyeloablative pretransplant...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: CTLA4Ig--

...METHODS & EQUIPMENT: marrow ***transplantation*** --

11/KWIC/2 (Item 2 from file: 5)
DIALOG(R)File 5:(c) 2006 The Thomson Corporation. All rts. reserv.

Stable mixed hematopoietic chimerism in dogs given CTLA4Ig and 100 cGy total body irradiation before and pharmacological immunosuppression after marrow transplant

1998

...REGISTRY NUMBERS: mycophenolate ***mofetil***

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...mycophenolate ***mofetil*** --

METHODS & EQUIPMENT: marrow transplantation--

11/KWIC/3 (Item 3 from file: 5)
DIALOG(R)File 5:(c) 2006 The Thomson Corporation. All rts. reserv.

Effects of mycophenolic acid mofetil on acute rejection of kidney allografts in rats

1996

ABSTRACT: Mycophenolic acid mofetil (MMF) is an agent which has recently gained a lot of attention. In clinical trials...

...study was to analyze the effects of MMF upon the expression of adhesion molecules in ***transplanted*** kidney allografts. LBNF1 kidneys were orthotopically transplanted into Lewis rats and either treated with MMF (20 mg/kg/day) or vehicle. Rats were harvested 3, 5 and 7 days following ***transplantation*** . Immunohistology was performed with various monoclonal antibodies. In general, MMF resulted in a better preservation of ***graft*** structure by 7 days. Cellular infiltration and tubular atrophy were less pronounced. At day 3...

...compared to controls. In addition, the number of cells positive for MHC class II and ***LFA*** -1 was reduced in the MMF-treated animals. In conclusion, MMF resulted in a markedly...

DESCRIPTORS:

MISCELLANEOUS TERMS: ... ***GRAFT*** STRUCTURE PRESERVATION...

...MYCOPHENOLIC ACID ***MOFETIL*** ; ...

... ***TRANSPLANTATION*** ;

11/KWIC/4 (Item 4 from file: 5)
DIALOG(R)File 5:(c) 2006 The Thomson Corporation. All rts. reserv.

1995

...ABSTRACT: of chronic allograft rejection, the most critical cause of late organ allograft loss. RS61443 (mycophenolate ***mofetil***) inhibits de novo DNA synthesis as well as diminishes expression of cell surface molecules and...

...with RS61443 (15 mg/kg/day, p.o.) was either initiated at the day of grafting (Gp 1) or 8 wks thereafter (Gp 2), and continued throughout the follow-up period...

...peaking at 12 wk; this binding was significantly inhibited by mAbs against specific adhesion molecules (***CD11a*** , CD18, and ICAM-1). Serum-allospecific IgG and IgM peaked at 1-2 wk after...

...REGISTRY NUMBERS: MYCOPHENOLATE ***MOFETIL***

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...MYCOPHENOLATE ***MOFETIL***

MISCELLANEOUS TERMS: ...MYCOPHENOLATE ***MOFETIL*** ;

11/KWIC/5 (Item 1 from file: 73)
DIALOG(R)File 73:(c) 2006 Elsevier B.V. All rts. reserv.

Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil

The novel immunosuppressive drug mycophenolate mofetil (CellCept(R), MMF) blocks DNA-synthesis by the inhibition of the enzyme inosine monophosphate dehydrogenase...

...application of MMF might lead to a reduction of cellular infiltrates in the course of ***transplant*** rejection. To evaluate the therapeutic value of MMF, we investigated to what extent MMF blocks...

...of T-cell adhesion ligands, the binding activity of lymphocytic leucocyte function associated antigen 1 (LFA-1), very late antigen 4 (VLA-4) and PSGL-1 (P-selectin glycoprotein ligand 1...

MEDICAL DESCRIPTORS:

DNA synthesis inhibition; cell infiltration; graft rejection; lymphocytic infiltration; endothelium cell; cell adhesion; vascular endothelium; cell membrane; pseudopodium; protein localization; human...

SECTION HEADINGS:

026 Immunology, Serology and Transplantation

037 Drug Literature Index

1998

11/KWIC/6 (Item 2 from file: 73)
DIALOG(R)File 73:(c) 2006 Elsevier B.V. All rts. reserv.

...against discrete molecular targets in the lymphocyte activation sequence has enabled the effective control of graft rejection by the use of combinatorial immunosuppressive therapy. Chimeric and humanized monoclonal antibodies against T...

...the cytokine release syndrome of first generation products. Biological blockade of co-stimulatory molecules including CD40L and CD28 produces immunological allograft unresponsiveness in primates, though this effect is not yet proven...

...use of microemulsion technology has increased the absorption and efficacy of cyclosporine in all organ transplants, so that there is little difference in efficacy between this agent and tacrolimus. Mycophenolate mofetil is not maximally effective alone, but significantly reduces the relative risk of acute rejection in...

...biological monitoring. Despite these advances, none of these interventions confers demonstrable long-term benefit in graft survival or function. Acute rejection can not therefore be assumed to be a

simple surrogate...

MEDICAL DESCRIPTORS:

*immunosuppressive treatment; *graft rejection
lymphocyte activation; target cell; graft survival; drug absorption;
drug efficacy; drug monitoring; cost benefit analysis; reporter gene; human
; review; priority...

SECTION HEADINGS:

026 Immunology, Serology and Transplantation

037 Drug Literature Index

1998

11/KWIC/7 (Item 3 from file: 73)

DIALOG(R)File 73:(c) 2006 Elsevier B.V. All rts. reserv.

Investigation of infiltration blocking properties of myophenolate
mofetil (cellcept(R))

UNTERSUCHUNGEN ZUR INFILTRATIONSHEMMENDEN EIGENSCHAFT VON MYCOPHENOLAT
MOFETIL (CELLCEPT(R))

Mycophenolate mofetil (MMF) suppresses cell mitosis by blocking
inosine- monophosphate-dehydrogenase (IMD). Because IMD is additionally
involved...

...of CD4+ or CD8+ T- lymphocytes to E-selectin but suppressed the cellular
interaction via ***LFA*** -1 or VLA-4 proteins. Therefore, beside its
antiproliferative effect MMF also possesses distinct infiltration...

MEDICAL DESCRIPTORS:

*graft rejection--drug therapy--dt

SECTION HEADINGS:

026 Immunology, Serology and Transplantation

037 Drug Literature Index

1997

11/KWIC/8 (Item 4 from file: 73)

DIALOG(R)File 73:(c) 2006 Elsevier B.V. All rts. reserv.

Synergistic effects of mycophenolate mofetil (MMF, RS-61443) and
anti- LFA-1/ICAM-1 monoclonal antibodies on the prolongation of heart
allograft survival in rats

MEDICAL DESCRIPTORS:

*graft rejection; *heart transplantation

animal experiment; animal model; conference paper; controlled study; drug
effect; drug potentiation; drug screening; graft survival; male;
nonhuman; oral drug administration; priority journal; rat

1996

11/KWIC/9 (Item 5 from file: 73)

DIALOG(R)File 73:(c) 2006 Elsevier B.V. All rts. reserv.

Mycophenolate mofetil inhibits lymphocyte binding and the
upregulation of adhesion molecules in acute rejection of rat kidney...

Mycophenolate mofetil (MMF) interacts with purine metabolism and
possibly with the expression of adhesion molecules. In the present study,
we analysed the expression of these molecules in transplanted kidney
allografts treated with RS LBNF1 kidneys were orthotopically
transplanted into Lewis rats and either treated with RS (20
mg/kg/day) or vehicle. Rats were harvested 3, 5 and 7 days following
transplantation . For binding studies, fresh-frozen sections of

transplanted kidneys were incubated with lymph node lymphocytes (LNL) derived from ***transplanted*** rats. Additionally, immunohistology was performed with various monoclonal antibodies. In general, MMF resulted in better preservation of ***graft*** structure by 7 days. Cellular infiltration and tubular atrophy were less pronounced. At day 3...

...that of controls. In addition, the number of cells positive for MHC class II and ***LFA*** -1 was reduced in the MMF-treated animals. These findings correlated with the binding results...

SECTION HEADINGS:

026 Immunology, Serology and Transplantation
028 Urology and Nephrology
037 Drug Literature Index
1996

11/KWIC/10 (Item 1 from file: 155)
DIALOG(R) File 155:(c) format only 2006 Dialog. All rts. reserv.

Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates.

... ***1999***
CD154 is the ligand for the receptor CD40. This ligand-receptor pair mediates endothelial and antigen...

... of these cells with T cells and platelets. We demonstrate here that administration of a CD154-specific monoclonal antibody (hu5C8) allows for renal allotransplantation in outbred, MHC-mismatched rhesus monkeys without...

... than 10 months after therapy termination, and no additional drug was required to achieve extended ***graft*** survival. Indeed, the use of tacrolimus or chronic steroids seemed to antagonize the anti-rejection effect. Monkeys treated with antibody against ***CD154*** remained healthy during and after therapy. The mechanism of action does not require global depletion...

... specific manner, but still formed donor-specific antibody and generated T cells that infiltrated the grafted organ without any obvious effect on ***graft*** function. Thus, therapy with antibody against ***CD154*** is a promising agent for clinical use in human allotransplantation.

Descriptors: *Antibodies, Monoclonal--pharmacology--PD; *Graft Rejection--drug therapy--DT; *Kidney Transplantation; *Membrane Glycoproteins--immunology--IM; Animals; Antibody Formation; CD40 Ligand; Graft Rejection--immunology--IM; Humans; Immunosuppressive Agents--pharmacology--PD; Interleukins--genetics--GE; Interleukins--metabolism--ME; Kidney...

Chemical Name: Antibodies, Monoclonal; Immunosuppressive Agents; Interleukins; Membrane Glycoproteins; Receptors, Antigen, T-Cell; Tacrolimus; L-Selectin; mycophenolate mofetil; CD40 Ligand; Mycophenolic Acid; RNA
?

s ctla4? and (lfa? or cd11a or cd11?) and (cd154 or cd40L or cd40(w)ligand or gp39)
and (transplant? or graft? or toleran?)

4839 CTLA4?
18887 LFA?
7402 CD11A
34995 CD11?
3221 CD154
7032 CD40L
28506 CD40
469767 LIGAND
13455 CD40(W)LIGAND
718 GP39
1710754 TRANSPLANT?
643312 GRAFT?
467303 TOLERAN?
S12 24 CTLA4? AND (LFA? OR CD11A OR CD11?) AND (CD154 OR CD40L
OR CD40(W)LIGAND OR GP39) AND (TRANSPLANT? OR GRAFT? OR
TOLERAN?)
? rd s12
S13 15 RD S12 (unique items)
? t s13/3/all

13/3/1 (Item 1 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014385244 BIOSIS NO.: 200300341987
Induction of operational tolerance to discordant dopaminergic porcine
xenografts.
AUTHOR: Larsson Lena C; Corbascio Matthias; Pearson Thomas C; Larsen
Christian P; Ekberg Henrik; Widner Hakan (Reprint)
AUTHOR ADDRESS: Section for Neuronal Survival, Wallenberg Neuroscience
Center, Lund University, S-221 84, BMC-A10, Lund, Sweden**Sweden
JOURNAL: Transplantation (Hagerstown) 75 (9): p1448-1454 May 15, 2003 2003
MEDIUM: print
ISSN: 0041-1337
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/2 (Item 2 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013614937 BIOSIS NO.: 200200208448
Simultaneous inhibition of B7 and LFA-1 signaling prevents rejection
of discordant neural xenografts in mice lacking CD40L
AUTHOR: Larsson Lena C (Reprint); Corbascio Matthias; Widner Hakan; Pearson
Thomas C; Larsen Christian P; Ekberg Henrik
AUTHOR ADDRESS: Section for Neuronal Survival, Wallenberg Neuroscience
Center, Lund University, BMC A10, S-221 84, Lund, Sweden**Sweden
JOURNAL: Xenotransplantation 9 (1): p68-76 January, 2002 2002
MEDIUM: print
ISSN: 0908-665X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/3 (Item 3 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0013598185 BIOSIS NO.: 200200191696

CTLA4IG induces long-term graft survival of allogeneic skin grafts and totally inhibits T-cell proliferation in LFA-1-deficient mice

AUTHOR: Malm Helene; Corbascio Matthias; Osterholm Cecilia; Cowan Shannon; Larsen Christian P; Pearson Thomas C; Ekberg Henrik (Reprint)

AUTHOR ADDRESS: Department of Nephrology and Transplantation, University Hospital, S-205 02, Malmo, Sweden**Sweden

JOURNAL: Transplantation (Baltimore) 73 (2): p293-297 January 27, 2002 2002

MEDIUM: print

ISSN: 0041-1337

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

13/3/4 (Item 4 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0012580531 BIOSIS NO.: 200000298844

Effect of factor VIII concentrate on antigen-presenting cell (APC)/T-cell interactions in vitro: Relevance to inhibitor formation and tolerance induction

AUTHOR: Hodge G (Reprint); Han P

AUTHOR ADDRESS: Department of Haematology, Women's and Children's Hospital, North Adelaide, SA, 5006, Australia**Australia

JOURNAL: British Journal of Haematology 109 (1): p195-200 April, 2000 2000

MEDIUM: print

ISSN: 0007-1048

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

13/3/5 (Item 1 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2006 Elsevier B.V. All rts. reserv.

13962700 EMBASE No: 2006381147

Costimulation blockade and its possible future use in clinical transplantation

Snanoudj R.; De Preneuf H.; Creput C.; Arzouk N.; Deroure B.; Beaudreuil S.; Durrbach A.; Charpentier B.

R. Snanoudj, Service de Nephrologie et Transplantation Renale, Hopital du Kremlin Bicetre, 78 R. du Gen. Leclerc, 94275 Le Kremlin-Bicetre France

AUTHOR EMAIL: renaud.snanoudj@bct.aphp.fr

Transplant International (TRANSPLANT INT.) (United Kingdom) 2006, 19/9 (693-704)

CODEN: TRINE ISSN: 0934-0874 eISSN: 1432-2277

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 95

13/3/6 (Item 2 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2006 Elsevier B.V. All rts. reserv.

12137869 EMBASE No: 2003248746

Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W FSub1 mice by a mechanism downstream of renal immune complex deposition

Schiffer L.; Sinha J.; Wang X.; Huang W.; Von Gonsdorff G.; Schiffer M.; Madaio M.P.; Davidson A.

Dr. A. Davidson, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461 United States

AUTHOR EMAIL: davidson@aecon.yu.edu

Journal of Immunology (J. IMMUNOL.) (United States) 01 JUL 2003, 171/1 (489-497)

CODEN: JOIMA ISSN: 0022-1767

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 45

13/3/7 (Item 1 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

15252284 PMID: 15567917

Chronic induction. What's new in the pipeline.

Vincenti Flavio

University of California, San Francisco, Calif. 94143-0780, USA.
vincentif@surgery.ucsf.edu

Contributions to nephrology (Switzerland) 2005, 146 p22-9, ISSN 0302-5144--Print Journal Code: 7513582

Publishing Model Print

Document type: Journal Article; Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

13/3/8 (Item 1 from file: 399)

DIALOG(R) File 399: CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

143265434 CA: 143(15)265434x PATENT

Methods based on binding of superantigen with T cell costimulatory pathway member for drug screening and for modulating Th1 cells to treat graft rejection, autoimmune, malignant and non-malignant proliferative diseases

INVENTOR(AUTHOR): Kaempfer, Raymond; Arad, Gila

LOCATION: Israel

PATENT: U.S. Pat. Appl. Publ. ; US 20050191296 A1 DATE: 20050901

APPLICATION: US 2004958765 (20041004) *IL 148993 (20020404) *WO 2003IL278 (20030403) *WO 2003IL839 (20031015) *WO 2004IL299 (20040401)

PAGES: 101 pp., Cont.-in-part of Appl. No. PCT/IL04/000299. CODEN:

USXXCO LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: 424144100; C07K-016/28A; A61K-039/395B; C07K-014/74B

13/3/9 (Item 2 from file: 399)

DIALOG(R) File 399: CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

142212344 CA: 142(12)212344r PATENT

Histone deacetylase inhibitors as immunosuppressants

INVENTOR(AUTHOR): Katopidis, Andreas

LOCATION: Switz.
ASSIGNEE: Novartis A.-G.; Novartis Pharma G.m.b.H.
PATENT: PCT International ; WO 200513958 A1 DATE: 20050217
APPLICATION: WO 2004EP8849 (20040806) *US 2003PV493320 (20030807)
PAGES: 44 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-031/16A; A61P-037/06B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ;
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
NE; SN; TD; TG

13/3/10 (Item 3 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

141420435 CA: 141(26)420435c PATENT
Method using an lck inhibitor with a calcineurin inhibitor or an
immunosuppressant for treating transplant rejection
INVENTOR(AUTHOR): Waegell, Wendy; Hirst, Gavin
LOCATION: USA
ASSIGNEE: Abbott Laboratories
PATENT: PCT International ; WO 2004100868 A2 DATE: 20041125
APPLICATION: WO 2004US12456 (20040423) *US PV464933 (20030423)
PAGES: 352 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ;
; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE;
BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL;
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;
SN; TD; TG

13/3/11 (Item 4 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

138152250 CA: 138(11)152250n PATENT
Method for detecting modulators of Notch signalling
INVENTOR(AUTHOR): Bodmer, Mark William; Briend, Emmanuel Cyrille Pascale;
Champion, Brian Robert; McKenzie, Grahame James; Tugal, Tamara; Ward,
George Albert; Young, Lesley Lynn
LOCATION: UK,
ASSIGNEE: Lorantis Limited
PATENT: PCT International ; WO 200312441 A1 DATE: 20030213
APPLICATION: WO 2002GB3397 (20020725) *GB 200118153 (20010725) *GB
20027930 (20020405) *GB 200212282 (20020528) *GB 200212283 (20020528)
PAGES: 184 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:

CLASS: G01N-033/50A; A61K-038/17B; A61P-037/00B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW;
AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW
; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES;
FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI; CM;
GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

13/3/12 (Item 5 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

136166058 CA: 136(11)166058b PATENT
Controlling immune responses by blocking T cell activation using
CTLA-4-binding surface proteins on antigen-presenting cells
INVENTOR(AUTHOR): Sheriff, Ahmed
LOCATION: Germany,
ASSIGNEE: Genethor G.m.b.H.
PATENT: PCT International ; WO 200212453 A1 DATE: 20020214
APPLICATION: WO 2001EP9161 (20010808) *DE 10038722 (20000809)
PAGES: 55 pp. CODEN: PIXXD2 LANGUAGE: German
PATENT CLASSIFICATIONS:

CLASS: C12N-005/16A; C07K-014/705B; A61K-035/14B; A61K-048/00B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI;
SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG;
KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ
; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC;
NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD;
TG

13/3/13 (Item 6 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

136052724 CA: 136(4)52724k PATENT
Methods for regulating a cell-mediated immune response by blocking
lymphocytic signals and by blocking LFA-1 mediated adhesion
INVENTOR(AUTHOR): Townsend, Robert M.; Todderud, Charles Gordon; Peach,
Robert J.
LOCATION: USA
ASSIGNEE: Bristol-Myers Squibb Company
PATENT: PCT International ; WO 200195928 A2 DATE: 20011220
APPLICATION: WO 2001US18619 (20010608) *US PV210671 (20000609)
PAGES: 75 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:

CLASS: A61K-038/17A; A61K-039/395B; A61P-037/00B; C07K-014/705B;
C07K-016/28B; A61K-039/395B; A61K-038/17B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI;
SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG;
KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ
; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC;

NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

13/3/14 (Item 7 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

134275763 CA: 134(20)275763g PATENT
Immunosuppressant agent for the treatment of cachexia and/or cardiogenic shock
INVENTOR(AUTHOR): Volk, Hans-Dieter; Anker, Stefan
LOCATION: Germany,
ASSIGNEE: Max-Delbrück-Centrum fuer Molekulare Medizin
PATENT: PCT International ; WO 200124782 A2 DATE: 20010412
APPLICATION: WO 2000DE3481 (20001004) *DE 19948126 (19991006)
PAGES: 23 pp. CODEN: PIXXD2 LANGUAGE: German
PATENT CLASSIFICATIONS:
CLASS: A61K-031/00A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CR; CU; CZ; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU;
ID; IL; IN; IS; JP; KE; KG; KP; KR; LZ; LK; LR; LS; LT; LU; LV; MA; MD;
MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ;
TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU;
TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW
; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE;
BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG -

13/3/15 (Item 8 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

124173443 CA: 124(13)173443d PATENT
Methods for inhibiting antigen specific T cell responses
INVENTOR(AUTHOR): Blazar, Bruce R.; Vallera, Daniel A.
LOCATION: USA
ASSIGNEE: Regents of the University of Minnesota
PATENT: PCT International ; WO 9534320 A2 DATE: 951221
APPLICATION: WO 95US7351 (950607) *US 255267 (940607) *US 472697 (950606)
PAGES: 61 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/00A; C07K-014/705B; C07K-014/725B; C07K-016/28B;
C07K-019/00B
DESIGNATED COUNTRIES: AU; CA; JP DESIGNATED REGIONAL: AT; BE; CH; DE; DK
; ES; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE
?